ORPHA:86830
Chronic myeloproliferative disease, unclassifiable
Also known as: CMPD-U · Undifferentiated myeloproliferative disease
Publications
630
89.5th percentile
Trials
46
Interventional, condition-specific
Researchers
1,614
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare hematological neoplasm characterized by clonal proliferation of myeloid precursors in the bone marrow, blood and other tissues (spleen, liver), with clinical, morphological and molecular features of myeloproliferative neoplasms (MPN), failing to meet criteria of a specific MPN. The presentation is nonspecific and variable and often includes leukocytosis, thrombocytosis and anemia. , as well as fatigue, malaise or weight loss may appear in advanced stages.
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019452
- UMLS:C1333046
- NCIT:C27350
Additional Mondo synonyms (9)
CMPD, U · MPN, U · MPN-U · chronic myeloproliferative disease, unclassifiable · chronic myeloproliferative disorder, unclassifiable · myeloproliferative neoplasm, unclassifiable · unclassifiable chronic myeloproliferative disease · unclassifiable chronic myeloproliferative disorder · undifferentiated myeloproliferative disease
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
630 matched papers (461 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
46 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
630
630 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
630 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
461 in the last 10 years · high confidence · 89.5th percentile (publications denominator)
Phrase hits: 630 · MeSH hits: 0
Who's working on it?
1,614
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Gangat N9 papers · 2025
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Papers in Europe PMC - 02Andersson TM6 papers · 2025
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Papers in Europe PMC - 03Bak M6 papers · 2026
Department of Haematology, Zealand University Hospital, University of Copenhagen, 4000 Roskilde, Denmark.
Papers in Europe PMC - 04George TI6 papers · 2026
Department of Pathology, School of Medicine, University of Utah, Salt Lake, UT, USA.
Papers in Europe PMC - 05Hultcrantz M6 papers · 2025
Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
Papers in Europe PMC - 06Orazi A6 papers · 2025
Department of Pathology, Texas Tech University Health Sciences Center, El Paso, TX, United States. Electronic address: Attilio.Orazi@ttuhsc.edu.
Papers in Europe PMC - 07Tefferi A6 papers · 2025
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA. tefferi.ayalew@mayo.edu.
Papers in Europe PMC - 08Xu Z6 papers · 2025
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China. xuzefeng@ihcams.ac.cn.
Papers in Europe PMC - 09Björkholm M5 papers · 2024
Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
Papers in Europe PMC - 10Cattaneo D5 papers · 2025
Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
46
interventional trials for this specific condition
46 interventional trials matched this specific condition name; none in our sample are currently recruiting.
Data as of 27 July 2026
46 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 96.9th percentile).
high confidence · 96.9th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
46 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Observational and natural-history studies
5 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07362225·RECRUITING·MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
Conditions: Polycythemia Vera · ET (Essential Thrombocythemia) · Polycythemia Vera (PV) · Essential Thrombocythemia (ET)·Matched via name phrase
- NCT05326919·RECRUITING·The Patient Cohort of the National Center for Precision Medicine in Leukemia
Conditions: Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · High-risk Myelodysplastic Syndrome · Secondary Myelofibrosis in Myeloproliferative Disease·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Chronic myeloproliferative disease, unclassifiable" OR "CMPD-U" OR "Undifferentiated myeloproliferative disease" OR "CMPD, U" OR "MPN, U" OR "MPN-U" OR "chronic myeloproliferative disorder, unclassifiable" OR "myeloproliferative neoplasm, unclassifiable" OR "unclassifiable chronic myeloproliferative disease" OR "unclassifiable chronic myeloproliferative disorder"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Chronic myeloproliferative disease, unclassifiable" OR "CMPD-U" OR "Undifferentiated myeloproliferative disease" OR "CMPD, U" OR "MPN, U" OR "MPN-U" OR "chronic myeloproliferative disorder, unclassifiable" OR "myeloproliferative neoplasm, unclassifiable" OR "unclassifiable chronic myeloproliferative disease" OR "unclassifiable chronic myeloproliferative disorder"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 46 interventional · 5 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T03:08:34.103Z